The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.
 
Kristen Keon Ciombor
Consulting or Advisory Role - Lilly; Merck; Personalis; Pfizer; Replimune; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Onyx (Inst); Pfizer (Inst); Pfizer/Calithera (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Array BioPharma
 
Tyler J. Zemla
No Relationships to Disclose
 
Joleen M. Hubbard
Consulting or Advisory Role - Bayer (Inst); BeiGene (Inst); Incyte (Inst); Incyte (Inst); Merck; Taiho Oncology (Inst)
Research Funding - Bayer (Inst); G1 Therapeutics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Pionyr (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Translational Research in Oncology (Inst); Treos Bio (Inst); Trovagene (Inst)
 
Jingquan Jia
Research Funding - Bayer (Inst); Genentech (Inst); Xilis (Inst)
 
Olumide B. Gbolahan
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Exelixis; Incyte; Merck Sharp & Dohme; QED Therapeutics
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - AstraZeneca/MedImmune (Inst)
 
Andrea Sousa
No Relationships to Disclose
 
Luke Wilson
No Relationships to Disclose
 
Blake Waechter
No Relationships to Disclose
 
Fang-Shu Ou
No Relationships to Disclose
 
Andrew B. Nixon
Consulting or Advisory Role - AdjuVolt; Leap Therapeutics; Promega
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Genmab (Inst); HTG Molecular Diagnostics (Inst); medpacto (Inst); Promega (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis